Table 2. Symptoms, vital signs and outcomes of patients infected with SARS-CoV-2 infection.
| All patients (N = 160) | Mild (n = 92) | Moderate (n = 19) | P value (Moderate vs Mild) | Severe (n = 49) | P value (severe vs Mild) | P value (Severe vs Moderate) | |
|---|---|---|---|---|---|---|---|
| Variables | |||||||
| Self-reported symptoms | |||||||
| Fever | 93 (58%) | 39 (42%) | 14 (74%) | 0.013* | 40 (82%) | <0.0001* | 0.470 |
| Cough | 92 (57%) | 45 (49%) | 13 (68%) | 0.041* | 34 (69%) | 0.007* | 0.854 |
| Fatigue | 87 (54%) | 34 (37%) | 12 (63%) | 0.036* | 41 (84%) | <0.0001* | 0.069 |
| Shortness of breath | 72 (45%) | 13 (14%) | 16 (84%) | <0.0001* | 43 (88%) | <0.0001* | 0.701 |
| Myalgia or arthralgia | 33 (21%) | 17 (18%) | 1 (5%) | - | 15 (31%) | - | - |
| Sore throat | 18 (11%) | 9 (10%) | 3 (18%) | - | 6 (12%) | - | - |
| Rhinorrhea | 16 (10%) | 8 (9%) | 2 (11%) | - | 6 (12%) | - | - |
| Vomiting | 12 (8%) | 3 (3%) | 3 (16%) | - | 6 (12%) | - | - |
| Diarrhea | 11 (7%) | 3 (3%) | 2 (11%) | - | 6 (12%) | - | - |
| Headache | 7 (4%) | 6 (7%) | 1 (5%) | - | 0 | - | - |
| Loss of appetite | 5 (3%) | 1 (1%) | 0 | - | 4 (8%) | - | - |
| Olfactory disorders | 2 (1%) | 2 (2%) | 0 | - | 0 | - | - |
| Vital signs upon admission | |||||||
| Respiratory rate (RR)_breaths/min | 22 (20–26) | 22 (20–22) | 24 (22–28) | 0.0006* | 27 (26–30) | <0.0001* | 0.021* |
| Dyspnea (RR ≥ 30 breaths/ minute) | 18 (11%) | 5 (5%) | 3 (16%) | - | 10 (20%) | <0.0001* | 0.004* |
| Temperatures _ °C | 36.8 (36.5–37.4) | 36.6 (36.4–36.9) | 37.3 (36.8–38.3) | 0.02* | 37.8 (36.5–38.3) | 0.025* | 0.080 |
| Temperature ≥ 38°C | 62 (39%) | 34 (37%) | 9 (47%) | 0.243 | 19 (39%) | 0.203 | 0.698 |
| SpO2 _% | 96 (86–98) | 98 (96–99) | 91 (90–97) | <0.0001* | 80 (62–87) | <0.0001* | <0.0001* |
| SpO2 < 95% | 58 (36%) | 5 (5%) | 12 (63%) | <0.0001* | 41 (84%) | <0.0001* | 0.112 |
| Heart rate (HR) _beats/min | 89 (84–104) | 85 (80–92) | 88 (85–112) | 0.042* | 103 (95–116) | <0.0001* | 0.143 |
| HR>100 beats/min | 56 (35%) | 13 (14%) | 8 (41%) | 0.012* | 35 (71%) | <0.0001* | 0.115 |
| Systolic blood pressure (SBP)_mmHg | 120 (110–135) | 120 (110–130) | 130 (120–140) | 0.013* | 130 (110–140) | 0.085 | 0.521 |
| SBP <90 mmHg | 3 (2%) | 1(1%) | 0 | - | 2 (4%) | - | - |
| ECG QTc _ms | 432 (407–458) | 424 (404–445) | 497 (434–507) | - | 441 (411–454) | - | - |
| ECG QTc ≥ 500 ms | 8 (5%) | 1 (1.1%) | 4 (21%) | - | 3 (6%) | - | - |
| Treatment | |||||||
| Hydroxychloroquine- Azithromycin | 147 (92%) | 88 (96%) | 17 (89%) | 0.280 | 42 (86%) | 0.048* | 0.683 |
| Oxygen support | 81 (51%) | 17 (18%) | 17 (89%) | <0.0001* | 47 (96%) | <0.0001* | 0.325 |
| Antibiotic therapy | 90 (56%) | 33 (36%) | 14 (74%) | 0.003* | 43 (87%) | <0.0001* | 0.184 |
| Dexamethasone | 5 (3%) | - | - | - | 5 (3%) | - | - |
| Invasive ventilation | 4 (2.5%) | - | - | - | 4 (8.2%) | - | - |
| Clinical evolution | |||||||
| Hospitalization duration | 15 (4–20) | 16 (13–21) | 19 (9–23) | 0.731 | 3.5 (1–15) | <0.0001* | 0.0002* |
| Outcome | - | - | - | 0.11 | - | <0.0001* | 0.008* |
| Discharge | 128 (80%) | 87 (95%) | 16 (84%) | - | 25 (51%) | - | - |
| Death | 32 (20%) | 5 (5%) | 3 (16%) | - | 24 (49%) | - | - |
Data are n (%) or median (IQR), SpO2: Peripheral oxygen saturation, SBP: Systolic blood pressure, ECG QTc: Electrocardiogram Corrected QT interval.